Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / beyond cancer selected to present on the clinical de mwn benzinga


XAIR - Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting | Benzinga

  • HAMILTON, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced being selected to present on the clinical development program of its Ultra-High Concentration Nitric Oxide (UNO) at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024 at the McCormick Place Convention Center in Chicago, Illinois. In addition, the Company will host a KOL event that will highlight the ongoing clinical development of UNO (additional details below).

    Company Sponsored Event:
    Beyond Cancer will host an event on May 31, 2024 featuring Key Opinion Leaders who will discuss the clinical development program for UNO, including new data from the Phase 1 trial. The event will take place at the Hyatt Regency McCormick Place, from 6:00 p.m. – 8:00 p.m. Central Time.

    To learn more and register for the company sponsored event please contact Matt Johnson at mjohnson@beyondcancer.com.

    ASCO Annual Meeting Presentations:

    Title: A phase 1, multi-center, safety, feasibility, and preliminary efficacy study evaluating a single dose of UNO101 in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies
    Session Date and Time: Saturday, June 1, 2024 at 9:00 a.m. – 12:00 p.m. Central Time
    Session Type and Title: Poster Presentation/Developmental Therapeutics - Immunotherapy
    Abstract Number: TPS2686
    Authors: Frederick M. Dirbas, Amichay Meirovitz, David Greenberg, Edith Dekel, Gavin Choy, Jedidiah M. Monson

    Title: Effect of UNO101 on tumor microenvironment in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies
    Session Type and Title: Publication Only; New Targets and New Technologies
    Abstract Number: e14575
    Authors: Amichay Meirovitz, David Greenberg, Mark Pegram, Jedidiah M. Monson

    A copy of the ePublication can be accessed on the Science and Technology page of the Company's website after May 23, 2024 at 5:00 p.m. ET when made available by ...

    Full story available on Benzinga.com

  • Stock Information

    Company Name: Beyond Air Inc.
    Stock Symbol: XAIR
    Market: NYSE
    Website: beyondair.net

    Menu

    XAIR XAIR Quote XAIR Short XAIR News XAIR Articles XAIR Message Board
    Get XAIR Alerts

    News, Short Squeeze, Breakout and More Instantly...